Novo Nordisk A/S (ETR:NOV)
Germany · Delayed Price · Currency is EUR | Market Cap | 156.08B -27.1% |
| Revenue (ttm) | 44.06B +5.6% |
| Net Income | 15.57B +4.8% |
| EPS | 3.50 +5.0% |
| Shares Out | n/a |
| PE Ratio | 10.07 |
| Forward PE | 11.93 |
| Dividend | 1.57 (4.43%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 40,868 |
| Open | 35.10 |
| Previous Close | 35.15 |
| Day's Range | 35.04 - 35.33 |
| 52-Week Range | 30.24 - 54.87 |
| Beta | 0.38 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs.
Bristol-Myers Squibb (BMY -0.91%) earns most of its revenue by commercializing complex prescription medications for cancer, cardiovascular conditions, and immunological diseases.
Where Will Novo Stock Be in 10 Years?
Novo remains a leader in the diabetes and weight loss drug markets. The company could make significant clinical and regulatory progress over the next few years.
Novo Nordisk's CagriSema Shows Promising Weight Loss Results, Boosting NVO Dividend Outlook
Novo Nordisk's CagriSema Shows Promising Weight Loss Results, Boosting NVO Dividend Outlook
Novo Nordisk Stock (NVO) Climbs 2% Today on Positive CagriSema Weight-Loss Data
Novo Nordisk stock gained on Tuesday alongside new weight-loss data from women who used CagriSema.
CagriSema: Novo Nordisk's Promising Weight Loss Drug Shows 25% Average Weight Reduction
CagriSema: Novo Nordisk's Promising Weight Loss Drug Shows 25% Average Weight Reduction
Novo Nordisk stock rises as CagriSema delivers 25% weight loss in women
Novo Nordisk shares NVO rose on Tuesday after the Danish drugmaker reported that its experimental weight-loss drug CagriSema helped women with obesity or overweight lose an average of 25% of their bod...
Novo Nordisk Reports 25% Weight Loss With CagriSema In Women; Stock Up
(RTTNews) - Novo Nordisk (NVO) reported results from two post hoc analyses of its Phase 3 REDEFINE 1 trial, showing that investigational CagriSema was associated with an average weight loss of 25% at ...
Novo Nordisk CagriSema Shows Significant Weight Loss Across Menopause Stages
(RTTNews) - Novo Nordisk (NVO) reported results from two post hoc analyses of its Phase 3 REDEFINE 1 trial, showing that investigational CagriSema was associated with an average weight loss of 25% at ...
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy. The Danish company said its next-generation ...
Novo's CagriSema helped women lose 25% of weight on average, analysis shows
Novo Nordisk said on Tuesday its next-generation experimental drug, CagriSema, showed 25% weight loss on average in women with obesity or overweight, according to data analyzed after the completion of...
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 19 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of...
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
A new government-funded study found that GLP-1 drugs slow the aging process in mice.
Eli Lilly's weight-loss pill wins EU drug regulator's backing
The European Medicines Agency's committee on Friday recommended approval of Eli Lilly's weight-loss pill Foundayo, making it the second oral weight-loss drug to win the agency's backing after Novo Nor...
Study Shows GLP-1 Benefits for Schizophrenia Patients, Boosting Novo Nordisk (NVO) Outlook
Study Shows GLP-1 Benefits for Schizophrenia Patients, Boosting Novo Nordisk (NVO) Outlook
Man claims he went blind after taking Ozempic, shares warning for other users
Todd Engel claims Ozempic caused his total vision loss from NAION and has filed a lawsuit against Novo Nordisk over inadequate drug warnings.
Evotec Appoints Former Novo Nordisk Executive Joanna Holbrook As Chief Scientific Officer; Stock Up
(RTTNews) - Evotec SE (EVO, EVTG.DE, EVTCY.PK), a life science company, announced the appointment of Dr. Joanna Holbrook as Chief Scientific Officer and member of the management board, effective Novem...
The Zacks Analyst Blog Highlights Walmart, Visa, Novo Nordisk, Village Super Market and Empire Petroleum
Walmart, Visa and Novo Nordisk headline Zacks' latest analyst reports, with digital growth, rising competition and earnings pressures shaping their outlooks.
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie is aggressively diversifying its pipeline to mitigate the revenue impact from its loss of patent exclusivity on Humira. Novo Nordisk maintains a dominant lead in the rapidly expanding metabolic...
Top Analyst Reports for Walmart, Visa & Novo Nordisk
Walmart, Visa and Novo Nordisk headline today's analyst reports, with digital growth, payment innovation and obesity-drug demand offset by rising costs and competition.
GLP-1 Drugs May Slow Aging By Upto Four Years, Early Research Suggest
(RTTNews) - New research from Novo Nordisk A/S (NVO) and Eli Lilly and Company (LLY) suggests that their GLP-1 drugs may slow down certain biological signs of aging by two to four years.
Novo Nordisk price target lowered to $40 from $47 at BMO Capital
BMO Capital lowered the firm’s price target on Novo Nordisk (NVO) to $40 from $47 and keeps a Market Perform rating on the shares as part of a broader research…
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Bristol Myers Squibb provides high free cash flow and a deep oncology pipeline at a modest valuation. Novo Nordisk dominates the obesity and diabetes markets with exceptional net margins and steady gr...
Novo Nordisk price target lowered to DKK 296 from DKK 310 at Citi
Citi analyst Graham Parry lowered the firm’s price target on Novo Nordisk (NVO) to DKK 296 from DKK 310 and keeps a Neutral rating on the shares. Published first on…
Citigroup Lowers Novo Nordisk's Target Price to 296 DKK Amid Long-Term Profit Concerns
Citigroup Lowers Novo Nordisk's Target Price to 296 DKK Amid Long-Term Profit Concerns